7.26

2.68% -0.20

Cormedix Inc (CRMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cormedix Inc stock is traded at $7.26, with a volume of 1.14M. It is down -2.68% in the last 24 hours and down -7.16% over the past month. Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Previous Close:

$7.46

Open:

$7.47

24h Volume:

1.14M

Relative Volume:

0.97

Market Cap:

$565.88M

Revenue:

$400.05M

Net Income/Loss:

$181.01M

P/E Ratio:

3.4583

EPS:

2.0993

Net Cash Flow:

$194.58M

1W Performance:

-1.63%

1M Performance:

-7.16%

6M Performance:

+1.82%

1Y Performance:

-27.98%

1-Day Range:

$7.235

$7.47

1-Week Range:

$7.1568

$7.695

52-Week Range:

$6.125

$13.02

Cormedix Inc Stock (CRMD) Company Profile

Name

Cormedix Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

908-517-9500

Address

389 INTERPACE PKWY, SUITE 450, PARSIPPANY

Employee

191

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

CRMD's Discussions on Twitter

Compare CRMD vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRMD Cormedix Inc	7.26	565.88M	400.05M	181.01M	194.58M	2.0993
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Cormedix Inc Stock (CRMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-23-26	Initiated	Oppenheimer	Outperform
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Leerink Partners	Outperform
Jan-13-25	Initiated	D. Boral Capital	Buy
Aug-26-24	Initiated	Rodman & Renshaw	Buy
Aug-10-23	Initiated	RBC Capital Mkts	Outperform
Feb-17-21	Initiated	Needham	Buy
Sep-29-20	Initiated	JMP Securities	Mkt Outperform
Sep-21-20	Initiated	Truist	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Mar-26-19	Reiterated	H.C. Wainwright	Buy
Dec-06-18	Initiated	ROTH Capital	Buy
Sep-25-17	Reiterated	H.C. Wainwright	Buy
Aug-10-17	Reiterated	Rodman & Renshaw	Buy
May-05-17	Reiterated	Rodman & Renshaw	Buy
Nov-11-16	Reiterated	FBR & Co.	Outperform
Mar-17-16	Reiterated	FBR Capital	Outperform
Mar-03-16	Initiated	FBR Capital	Outperform
Nov-16-15	Reiterated	ROTH Capital	Neutral
Oct-29-15	Reiterated	ROTH Capital	Neutral
May-06-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-08-14	Reiterated	ROTH Capital	Buy
Oct-03-11	Downgrade	Maxim Group	Buy → Hold

View All

Cormedix Inc Stock (CRMD) Latest News

Oct 09, 2026

RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $14 - Moomoo

Oct 09, 2026

Oct 08, 2026

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? - Zacks Investment Research

Oct 08, 2026

CorMedix Inc (NASDAQ:CRMD) Stock Now Rated "Moderate Buy" by Wall Street Analysts - MarketBeat

Oct 03, 2026

Oct 02, 2026

150,656 Shares in CorMedix Inc $CRMD Acquired by Bank of America Corp DE - MarketBeat

Oct 02, 2026

Oct 01, 2026

CorMedix Inc. R (19KA.F) Q1 FY2026 earnings call transcript - Yahoo Finance

Oct 01, 2026

Sep 30, 2026

Diluted net income available to common stockholders of CorMedix Inc. – HAN:19KA - TradingView

Sep 30, 2026

Non-operating income (total) of CorMedix Inc. – HAN:19KA - TradingView

Sep 30, 2026

Sep 29, 2026

Price to cash flow ratio of CorMedix Inc. – HAN:19KA - TradingView

Sep 29, 2026

Cash flow from financing activities of CorMedix Inc. – HAN:19KA - TradingView

Sep 29, 2026

ETFs Investing in CorMedix Inc. Stocks - TradingView

Sep 29, 2026

CorMedix Inc. Balance Sheet – HAN:19KA - TradingView

Sep 29, 2026

Return on assets % of CorMedix Inc. – HAN:19KA - TradingView

Sep 29, 2026

Enterprise value of CorMedix Inc. – HAN:19KA - TradingView

Sep 29, 2026

CorMedix Inc. Revenue Breakdown – HAN:19KA - TradingView

Sep 29, 2026

Sep 27, 2026

Form 4 CorMedix Inc For: 27 September - Investing.com India

Sep 27, 2026

Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Form 4 CorMedix Inc For: 27 September By Investing.com - Investing.com UK

Sep 27, 2026

Is CRMD Stock a Buy Now After Strong Growth and New Risks? - Eastern Progress

Sep 27, 2026

Sep 26, 2026

The Technical Signals Behind (CRMD) That Institutions Follow - Stock Traders Daily

Sep 26, 2026

Sep 25, 2026

Cormedix Inc Lobbying Profile, 2015 - OpenSecrets

Sep 25, 2026

Sep 23, 2026

CorMedix (NASDAQ:CRMD) Shares Gap UpStill a Buy? - MarketBeat

Sep 23, 2026

CRMD Shareholder Alert: Rosen, a Longstanding and Trusted Firm, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionCRMD - TMX Newsfile

Sep 23, 2026

Oppenheimer Initiates CorMedix at Outperform With $15 Price Target - Moomoo

Sep 23, 2026

Oppenheimer Initiates CorMedix at Outperform With $15 Price Target - marketscreener.com

Sep 23, 2026

CorMedix (NASDAQ:CRMD) Coverage Initiated by Analysts at Oppenheimer - MarketBeat

Sep 23, 2026

Oppenheimer initiates CorMedix stock coverage with outperform rating - Investing.com

Sep 23, 2026

Sep 20, 2026